22-May-2025 3:30 PM CST - Business Wire QuidelOrtho to Participate in Upcoming Investor Conferences QuidelOrtho Corporation (Nasdaq: QDEL) (QuidelOrtho), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 45th Annual Growth Stock Conference, Wednesday, June 4, 2025 Members of QuidelOrthos management team will participate in a presentation at 9:00 a.m. ET
7-May-2025 3:05 PM CST - Business Wire QuidelOrtho Reports First Quarter 2025 Financial Results QuidelOrtho Corporation (Nasdaq: QDEL) (the Company or QuidelOrtho), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 30, 2025. We delivered solid first quarter performance driven by growth in our Labs business and the strength of our recurring revenue business model, said Brian J. Blaser, President an
23-Apr-2025 3:30 PM CST - Business Wire QuidelOrtho to Report First Quarter 2025 Financial Results QuidelOrtho Corporation (Nasdaq: QDEL) (the Company) or (QuidelOrtho), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at
24-Feb-2025 6:00 AM CST - Business Wire QuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor Conference QuidelOrtho Corporation (NASDAQ: QDEL) (QuidelOrtho), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 46th Annual Raymond James Institutional Investor Conference on Wednesday, March 5, 2025. Members of QuidelOrthos management team will participate in a presentation at 8:40 a.m. ET / 5:40 a.m. PT.
12-Feb-2025 3:05 PM CST - Business Wire QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results QuidelOrtho Corporation (Nasdaq: QDEL) (the Company or QuidelOrtho), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter and full-year ended December 29, 2024. We are pleased with our 2024 business performance and ended the year with positive momentum leading into 2025, said Brian J. Blaser, President and Chief Execu
13-Jan-2025 8:00 AM CST - Business Wire QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024 QuidelOrtho Corporation (Nasdaq: QDEL) (the Company or QuidelOrtho), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue for the fourth quarter ended December 29, 2024. Fourth Quarter 2024 Preliminary Unaudited Revenues The Company expects total reported revenues for the fourth quarter of 2024 to be in the range of approximately
31-Dec-2024 6:00 AM CST - Business Wire QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference QuidelOrtho Corporation (Nasdaq: QDEL) (QuidelOrtho), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. The Companys presentation is scheduled for Monday, January 13, 2025 at 7:30 a.m. PST / 10:30 a.m. EST. Interested parties can access the live webcast
7-Nov-2024 3:05 PM CST - Business Wire QuidelOrtho Reports Third Quarter 2024 Financial Results QuidelOrtho Corporation (Nasdaq: QDEL) (the Company or QuidelOrtho), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the third quarter ended September 29, 2024. We delivered solid third quarter results, giving us confidence that our strategic priorities and focus on our customers, business growth and margin improvement are gaining
28-Oct-2024 6:00 AM CST - Business Wire QuidelOrtho to Participate in Three Upcoming Investor Conferences QuidelOrtho Corporation (Nasdaq: QDEL) (the Company or QuidelOrtho), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend three upcoming investor conferences and participate in fireside chats at all three conferences. UBS Global Healthcare Conference On Tuesday, November 12, 2024, QuidelOrtho is scheduled to part
22-May-2025 3:30 PM CST - Business Wire QuidelOrtho to Participate in Upcoming Investor Conferences QuidelOrtho Corporation (Nasdaq: QDEL) (QuidelOrtho), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 45th Annual Growth Stock Conference, Wednesday, June 4, 2025 Members of QuidelOrthos management team will participate in a presentation at 9:00 a.m. ET
7-May-2025 3:05 PM CST - Business Wire QuidelOrtho Reports First Quarter 2025 Financial Results QuidelOrtho Corporation (Nasdaq: QDEL) (the Company or QuidelOrtho), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 30, 2025. We delivered solid first quarter performance driven by growth in our Labs business and the strength of our recurring revenue business model, said Brian J. Blaser, President an
23-Apr-2025 3:30 PM CST - Business Wire QuidelOrtho to Report First Quarter 2025 Financial Results QuidelOrtho Corporation (Nasdaq: QDEL) (the Company) or (QuidelOrtho), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at
24-Feb-2025 6:00 AM CST - Business Wire QuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor Conference QuidelOrtho Corporation (NASDAQ: QDEL) (QuidelOrtho), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 46th Annual Raymond James Institutional Investor Conference on Wednesday, March 5, 2025. Members of QuidelOrthos management team will participate in a presentation at 8:40 a.m. ET / 5:40 a.m. PT.
12-Feb-2025 3:05 PM CST - Business Wire QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results QuidelOrtho Corporation (Nasdaq: QDEL) (the Company or QuidelOrtho), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter and full-year ended December 29, 2024. We are pleased with our 2024 business performance and ended the year with positive momentum leading into 2025, said Brian J. Blaser, President and Chief Execu
13-Jan-2025 8:00 AM CST - Business Wire QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024 QuidelOrtho Corporation (Nasdaq: QDEL) (the Company or QuidelOrtho), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue for the fourth quarter ended December 29, 2024. Fourth Quarter 2024 Preliminary Unaudited Revenues The Company expects total reported revenues for the fourth quarter of 2024 to be in the range of approximately
31-Dec-2024 6:00 AM CST - Business Wire QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference QuidelOrtho Corporation (Nasdaq: QDEL) (QuidelOrtho), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. The Companys presentation is scheduled for Monday, January 13, 2025 at 7:30 a.m. PST / 10:30 a.m. EST. Interested parties can access the live webcast
7-Nov-2024 3:05 PM CST - Business Wire QuidelOrtho Reports Third Quarter 2024 Financial Results QuidelOrtho Corporation (Nasdaq: QDEL) (the Company or QuidelOrtho), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the third quarter ended September 29, 2024. We delivered solid third quarter results, giving us confidence that our strategic priorities and focus on our customers, business growth and margin improvement are gaining
28-Oct-2024 6:00 AM CST - Business Wire QuidelOrtho to Participate in Three Upcoming Investor Conferences QuidelOrtho Corporation (Nasdaq: QDEL) (the Company or QuidelOrtho), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend three upcoming investor conferences and participate in fireside chats at all three conferences. UBS Global Healthcare Conference On Tuesday, November 12, 2024, QuidelOrtho is scheduled to part
